Researchers Developed Sensor for Parkinson's Detection
A new blood test identified Parkinson's-related protein profiles with 90.9 per cent accuracy in an initial study.
Updated on Oct. 12, 2026 in Stroke
Live Poll
Would you want a blood test to screen for Parkinson's years before symptoms appear?
Researchers at the University of Oxford and KAUST have created a novel sensor capable of detecting Parkinson's disease through a blood test. The diagnostic tool successfully identified specific protein markers in a study involving 59 participants.
Why it matters
Measuring multiple forms of the alpha-synuclein protein simultaneously may provide clearer diagnostic insights than traditional single-marker approaches. This development could eventually lead to more efficient identification of the condition.
The sensor measures three forms of alpha-synuclein protein to deliver results within 40 minutes. The pilot study included individuals with diagnosed Parkinson's, healthy subjects, and those with isolated REM sleep behaviour disorder.
The players
University of Oxford
This is a collegiate research university based in England that collaborated on the development of the Parkinson's diagnostic sensor.
KAUST
King Abdullah University of Science and Technology is a graduate-level research university located in Saudi Arabia that partnered on this study.
The details
The sensor works by identifying low concentrations of molecular signals in the bloodstream linked to the disease. By examining multiple forms of alpha-synuclein together, the team aims to improve the sensitivity of detecting Parkinson's-related profiles.
Timeline
October 12, 2026: The study and sensor development were formally published.
The Big Picture
This development represents a shift toward liquid biopsy diagnostics for neurological disorders, moving away from current reliance on symptom-based clinical evaluation. This study followed established protocols from the Oxford Discovery cohort to test the viability of protein-based screening.
The new blood test could eventually provide a faster, less invasive diagnostic process for patients currently awaiting neurological evaluations. Widespread clinical use remains contingent on future long-term studies that will confirm the sensor's reliability across larger populations.
The takeaway
Early detection of neurodegenerative biomarkers is becoming increasingly feasible through rapid blood-based testing methods. Future diagnostic tools will likely rely on these multi-marker profiles to provide earlier intervention opportunities for patients.
Further reading
Learn more about the latest innovations in neurodegenerative diagnostics in the Stroke section.
Source note: This article includes information reported by Oxford Mail.
Live Poll
Would you want a blood test to screen for Parkinson's years before symptoms appear?
